Search Results for "Constipation"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Constipation. Results 151 to 160 of 299 total matches.
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
oxyhydroxide, while nausea and constipation
were more common with sevelamer carbonate.
As with other iron ...
Most patients with end-stage renal disease develop
hyperphosphatemia, which can lead to secondary hyperparathyroidism,
vascular calcification, and cardiovascular
mortality. The FDA has approved sucroferric oxyhydroxide
(Velphoro – Fresenius Medical Care), a chewable
phosphate binder, for treatment of hyperphosphatemia in
patients with chronic kidney disease (CKD) on dialysis. It
is the first iron-based phosphate binder to be approved for
this indication.
Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
-like illness, injectionsite
pain, nausea, vomiting, diarrhea, constipation,
headache, myalgia ...
The FDA has approved talimogene laherparepvec
(Imlygic – Amgen), a genetically modified herpes
simplex virus, for intralesional treatment of
unresectable cutaneous, subcutaneous, and nodal
lesions in patients with melanoma that has recurred
following surgery. It is the first oncolytic virotherapy to
become available in the US.
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
with placebo included musculoskeletal pain,
peripheral edema, gout, and constipation.
The incidence ...
Icosapent ethyl (Vascepa – Amarin), the ethyl ester
of eicosapentaenoic acid (EPA), has been approved
by the FDA for use as an adjunct to maximally
tolerated statin therapy to reduce the risk of major
adverse cardiovascular events in adults with
hypertriglyceridemia (≥150 mg/dL) who have either
established cardiovascular disease (CVD) or diabetes
and ≥2 additional risk factors for CVD. It is the only
omega-3 polyunsaturated fatty acid (PUFA) product
to be approved in the US for this indication. Icosapent
ethyl and two other omega-3 PUFA prescription
products (Lovaza, Epanova),...
Plenity for Weight Management
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
%), and constipation (5.4%). Most
of these effects were mild, occurred within the first
3 months of treatment ...
Plenity (Gelesis), a nonsystemic oral superabsorbent
hydrogel formulation of cellulose and citric acid is
now available. It was cleared by the FDA in 2019 to
aid in weight management together with diet and
exercise in overweight and obese adults (BMI of
25-40 kg/m2). It is classified by the FDA as a device
because the contents of the capsule are not absorbed
systemically. Plenity is the first ingested, transient,
space-occupying hydrogel to be marketed in the US
and the only weight management treatment available
by prescription for patients with a BMI of 25-30 kg/m2,
regardless of...
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
, and pain, muscle spasms, insomnia,
abdominal pain, constipation, diarrhea, dizziness,
abnormal dreams ...
A once-weekly transdermal formulation of the
acetylcholinesterase inhibitor donepezil (Adlarity –
Corium) has been approved by the FDA for
treatment of mild, moderate, and severe Alzheimer's
disease (AD) dementia. Donepezil is the second
acetylcholinesterase inhibitor to become available in
a transdermal formulation; transdermal rivastigmine
(Exelon Patch), which is applied once daily, has been
available for years for the same indication. Donepezil
is also available in oral formulations (Aricept, and
generics) for treatment of AD dementia.
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
(frequency ≥20%) include paronychia,
musculoskeletal pain, dyspnea, cough, nausea,
stomatitis, constipation ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
, fatigue,
upper respiratory tract infection, nausea, headache,
diarrhea, constipation, and cough ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on response rate. Teclistamab is the first
bispecific BCMA-directed CD3 T-cell engager to be
approved in the US.
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
of GERD symptoms.
Adverse Effects – Aluminum and calcium carbonate
can cause constipation, and magnesium ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Transdermal Fentanyl
The Medical Letter on Drugs and Therapeutics • Oct 16, 1992 (Issue 881)
fentanyl. Erythema and pruritus at the site of application,
sweating, nausea, vomiting, constipation, dry ...
Fentanyl, a synthetic opioid previously available for parenteral use in anesthesia (Sublimaze), has now been marketed in a controlled-release transdermal formulation (Duragesic - Janssen) for use in patients with chronic pain severe enough to require opioid analgesia. It is not recommended for treatment of postoperative pain because of the drug's slow onset and prolonged duration of action.
New Advertisement for An Old Antihistamine
The Medical Letter on Drugs and Therapeutics • Jan 22, 1993 (Issue 888)
, constipation, and abdominal
pain. Clemastine is probably less sedating than diphenhydramine or a phenothiazine ...
Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.